

**Form 51-102F3**  
***Material Change Report***

**1. Name and Address of Company**

**Enttheon Biomedical Corp.**  
Suite 720 - 999 W Broadway Street  
Vancouver, BC  
V5Z 1K5  
(the "Company")

**2. Dates of Material Change(s)**

January 6, 2023

**3. News Release(s)**

News release was issued on January 6, 2023 and disseminated via Stockwatch pursuant to section 7.1 of National Instrument 51-102.

**4. Summaries of Material Changes**

The Company announces the appointment of Soo-Whan Kim as Interim Chief Financial Officer of the Company replacing Brandon Schwabe as Chief Financial Officer.

**5. Full Description of Material Changes**

News Release dated January 6, 2023– See Schedule "A".

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**7. Omitted Information**

No information has been omitted.

**8. Executive Officer**

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

**9. Date of Report**

This report is dated January 10, 2023

## Entheon Announces New Interim Chief Financial Officer

Vancouver, British Columbia--(January 6, 2023) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce the appointment of Soo-Whan Kim as Interim Chief Financial Officer of the Company, effective immediately. Mr. Kim brings over 12 years of experience working in senior finance positions of publicly traded companies. Mr. Kim serves as the Chief Financial Officer of Western Metallica Resources Corp. and as Corporate Controller of Consolidated Uranium and Labrador Uranium. He was previously Director of Treasury & Planning at Americas Gold & Silver and Corporate Controller at Andean Precious Metals and Polar Star Mining. Mr. Kim began his career at BDO Canada where he worked with numerous companies across various sectors. Mr. Kim is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce from the Ted Rogers School of Management at Toronto Metropolitan University. Mr. Kim replaces Brandon Schwabe as Chief Financial Officer.

### **About Entheon Biomedical Corp.**

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

### **On Behalf of the Board of Directors,**

Timothy Ko, CEO, President and Director

### **For more information, please contact the Company at:**

Entheon Biomedical Corp.

Timothy Ko, CEO

[timothy@entheonbiomedical.com](mailto:timothy@entheonbiomedical.com)

<https://entheonbiomedical.com/>